Skip to content

News from ISGD

Dr. Howard TrachtmanAugust 22, 2024< 1 min read

PARASOL Interim Meeting Report

After a successful meeting in December 2023 to launch the PARASOL initiative, the group ...
Start Reading
Laurel DamashekAugust 2, 2024< 1 min read

NEJM "Science behind the Study" Editorial: Kidney Disease and Antinephrin Antibodies

Don't miss the new "Science behind the Study" editorial by Jochen Reiser, MD, PhD ...
Start Reading
Laurel DamashekMay 25, 20245 min read

Anti-nephrin autoantibodies in minimal change disease and idiopathic NS

New research demonstrates role of anti-nephrin autoantibodies as causative factor and ...
Start Reading
Laurel DamashekApril 27, 2024< 1 min read

FSGS and NS Research Funding Opportunities Through PRMRP

The US Department of Defense includes FSGS and nephrotic syndrome as two of the priority ...
Start Reading
Laurel DamashekApril 22, 20242 min read

ISGD President Tobias B. Huber Awarded Prestigious ERC Advanced Grant to Study FSGS

Professor Dr. Tobias B. Huber, the inaugural President of the International Society of ...
Start Reading
Laurel DamashekDecember 22, 20233 min read

New Era Act Introduced in Congress

We are thrilled to share that the New Era of Preventing End-Stage Kidney Disease Act ...
Start Reading
Laurel DamashekDecember 20, 20232 min read

Announcing the PARASOL Project: PROTEINURIA AND GFR AS CLINICAL TRIAL ENDPOINTS IN FOCAL SEGMENTAL GLOMERULOSCLEROSIS

ISGD is collaborating in a multidisciplinary effort to tackle the urgent problem of ...
Start Reading
Dr. Kenar JhaveriAugust 25, 20232 min read

EXPLORING THE NICHE: GLOMERULAR DISEASE MANAGEMENT IN NEPHROLOGY

Navigating the complexities of glomerular diseases (GD) in nephrology is no small feat. ...
Start Reading
Laurel DamashekAugust 18, 20231 min read

Addressing the Unequal Burden of Kidney Disease on Black Americans

As kidney specialists, I'm sure we all know the statistic that chronic kidney disease is ...
Start Reading
Laurel DamashekAugust 15, 20231 min read

The AFFINITY Study: Seeking 20 FSGS Patients

The AFFINITY study is a global, open-label, phase 2 basket trial evaluating the safety ...
Start Reading